Orchid Pharma Ltd Financials
Company Logo

Orchid Pharma Ltd Financial Statement

Orchid Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue243.74
Operating Expense203.15
Net Profit27.85
Net Profit Margin11.43
Earning Per Share5.49
EBIDTA40.59
Effective Tax RateTBA

Orchid Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual819.37
Operating Expenses Annual708.69
Operating Profit Annual141.07
Interest Annual16.33
Depreciation31.75
Net Profit Annual94.75
Tax Annual-3.23

Orchid Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning18.31
Cash Flow from Operations130.73
Cash Flow from Investing-315.81
Cash Flow from Financing167.07
Cash Flow at the End0.29

Orchid Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)17.26
PBIT Margin (%)13.21
PBT Margin (%)12.42
Net PROFIT Margin (%)11.56
Return On Networth / Equity (%)3.15
Return On Networth /Employed (%)3.33
Return On Assets (%)7.75
Total Debt / Equity (X)0.24
Asset Turnover Ratio (%)0.67

Orchid Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual630.71
Total Current Assets Annual782.29
Non Current Assets Annual769.91
Total Shareholders Funds Annual1,218.32
Total Assets Annual1,552.20

Orchid Pharma Ltd Earning Calls

EPS (INR)

Expected

4.39

Reported

4.40

Surprise

0.23%

Dec 2024

EPS beaten by 0.23%

Sep 2024

EPS beaten by 0.00%

Jun 2024

EPS beaten by 0.00%

FAQS on Orchid Pharma Ltd Financials

As of May 30, 2025, Orchid Pharma Ltd has a market capitalization of 3,940.37 Cr. Value Research classifies it as a Mid-Cap company.

Yes, Orchid Pharma Ltd is with a debt-to-equity ratio of 0.13.

In FY 2024 , Orchid Pharma Ltd recorded a total revenue of approximately 921.93 Cr marking a significant milestone in the company's financial performance.

Orchid Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.5% and 0.2% annually, respectively..

Orchid Pharma Ltd's current PE ratio is 37.01.

Orchid Pharma Ltd's ROCE averaged 6.9% from the FY ending March 2023 to 2025, with a median of 8.0%. It peaked at 8.1% in March 2025, reflecting strong capital efficiency over the period..

Orchid Pharma Ltd's latest EBIT is Rs. 121.02 Cr, surpassing the average EBIT of Rs. 105.10 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions